Table 1.
Patient characteristics and comparison of azithromycin-resistant Mycoplasma genitalium episodes vs. all other episodes
| All episodes N = 199 |
Azithromycin resistance negative or non-available episodes N = 121 |
Azithromycin-resistant episodes N = 78 |
p value | |
|---|---|---|---|---|
| Age | 35.6 ± 10.7 | 34.9 ± 11.7 | 36.9 ± 9.0 | 0.203 |
| Male | 93% (185/199) | 89% (108/121) | 99% (77/78) | 0.011 |
| MSM | 81% (161/199) | 73% (88/121) | 94% (73/78) | <0.001 |
| On HIV PrEP | 39% (78/199) | 35% (42/121) | 46% (36/78) | 0.106 |
| HIV | 33% (65/199) | 30% (36/121) | 37% (29/78) | 0.275 |
| History of HIV PEP | 12% (23/199) | 10% (12/121) | 14% (11/78) | 0.367 |
| History of syphilis | 44% (87/199) | 42% (51/121) | 46% (36/78) | 0.578 |
| Leading symptom | ||||
| Asymptomatic | 68% (135/199) | 65% (79/121) | 72% (56/78) | 0.004 |
| Urethritis | 22% (43/199) | 27% (33/121) | 13% (10/78) | |
| Proctitis | 8% (15/199) | 3% (4/121) | 14% (11/78) | |
| Pharyngitis | 1% (1/199) | 1% (1/121) | 0% (0/78) | |
| Cervicitis | 3% (5/199) | 3% (4/121) | 1% (1/78) | |
| Site of manifestationa | ||||
| Urethral | 55% (110/199) | 67% (81/121) | 37% (29/78) | <0.001 |
| Anal | 40% (80/199) | 28% (34/121) | 59% (46/78) | |
| Pharyngeal | 2% (4/199) | 2% (2/121) | 3% (2/78) | |
| Cervical | 3% (5/199) | 3% (4/121) | 1% (1/78) | |
| Treatment | 89% (178/199) | 89% (108/121) | 90% (70/78) | 0.913 |
| Doxycycline | 11% (21/178) | 13% (14/108) | 10% (7/70) | 0.580 |
| Negative follow-up test | 63% (5/8) | 57% (4/7) | 100% (1/1) | – |
| Azithromycin | 52% (92/178) | 84% (91/108) | 1% (1/70) | <0.001 |
| Negative follow-up test | 76% (44/58) | 76% (44/58) | – | – |
| Moxifloxacin | 37% (65/178) | 3% (3/108) | 89% (62/70) | <0.001 |
| Negative follow-up test | 85% (34/40) | N/A | 85% (34/40) | – |
| Concomitant infection | ||||
| Gonorrhea | 13% (26/199) | 13% (16/121) | 13% (10/78) | 1 |
| Chlamydia | 19% (37/199) | 22% (27/121) | 13% (10/78) | 0.093 |
| Syphilis | 14% (28/199) | 11% (13/121) | 19% (15/78) | 0.093 |
HIV human immunodeficiency virus, MSM men who have sex with men, PEP post-exposure prophylaxis, PrEP pre-exposure prophylaxis
a 17 individuals were tested positive at more than one location: all seventeen tested positive at the urethra plus 12 and 5 at the anal mucosa and cervix, respectively. For the purpose of this analysis, these 17 cases were assigned to the non-urethral (i.e., anal or cervical) site only